Alexander C Huang

List of Publications by Year in Descending Order

32 papers	6,267 citations	20 h-index	37 g-index
37 ext. papers	9,183 ext. citations	24.3 avg, IF	5.16 L-index

#	Paper	IF	Citations
32	BAMM (BRAF Autophagy and MEK inhibition in Melanoma): A phase I/II trial of dabrafenib, trametinib and hydroxychloroquine in advanced melanoma.. *Clinical Cancer Research*, **2022**,	12.9	3
31	Human epigenetic and transcriptional T cell differentiation atlas for identifying functional T cell-specific enhancers.. *Immunity*, **2022**, 55, 557-574.e7	32.3	0
30	A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance.. *Nature Immunology*, **2022**,	19.1	9
29	Signaling Through FcRIIA and the C5a-C5aR Pathway Mediate Platelet Hyperactivation in COVID-19.. *Frontiers in Immunology*, **2022**, 13, 834988	8.4	1
28	Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19. *Science Immunology*, **2021**, 6,	28	74
27	Role of nuclear localization in the regulation and function of T-bet and Eomes in exhausted CD8 T cells. *Cell Reports*, **2021**, 35, 109120	10.6	13
26	CD8 T cells contribute to survival in patients with COVID-19 and hematologic cancer. *Nature Medicine*, **2021**, 27, 1280-1289	50.5	103
25	Dichotomous and stable gamma delta T-cell number and function in healthy individuals **2021**, 9,		7
24	SARS-CoV-2 Seropositivity and Seroconversion in Patients Undergoing Active Cancer-Directed Therapy. *JCO Oncology Practice*, **2021**, 17, e1879-e1886	2.3	1
23	Association of Antibiotic Exposure With Survival and Toxicity in Patients With Melanoma Receiving Immunotherapy. *Journal of the National Cancer Institute*, **2021**, 113, 162-170	9.7	31
22	Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial. *JAMA Internal Medicine*, **2021**, 181, 195-202	11.5	102
21	Rates of COVID-19-Related Outcomes in Cancer Compared With Noncancer Patients. *JNCI Cancer Spectrum*, **2021**, 5, pkaa120	4.6	8
20	Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. *Nature Communications*, **2021**, 12, 346	17.4	34
19	Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). *Nature Medicine*, **2021**, 27, 301-309	50.5	65
18	CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancer **2021**,		11
17	Alpha-Fetoprotein-Producing Lung Hepatoid Adenocarcinoma with Brain Metastasis Treated with S-1. *Case Reports in Oncology*, **2020**, 13, 1552-1559	1	5
16	Developmental Relationships of Four Exhausted CD8 T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms. *Immunity*, **2020**, 52, 825-841.e8	32.3	172

List of Publications

15	Deep immune profiling of COVID-19 patients reveals patient heterogeneity and distinct immunotypes with implications for therapeutic interventions **2020**,		52
14	Neoadjuvant Versus Adjuvant Immune Checkpoint Blockade in the Treatment of Clinical Stage III Melanoma. *Annals of Surgical Oncology*, **2020**, 27, 2915-2926	3.1	5
13	Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. *Science*, **2020**, 369,	33.3	744
12	Postvaccination graft dysfunction/aplastic anemia relapse with massive clonal expansion of autologous CD8+ lymphocytes. *Blood Advances*, **2020**, 4, 1378-1382	7.8	8
11	A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. *Nature Medicine*, **2019**, 25, 454-461	50.5	283
10	TOX transcriptionally and epigenetically programs CD8 T cell exhaustion. *Nature*, **2019**, 571, 211-218	50.4	459
9	TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision. *Immunity*, **2019**, 51, 840-855.e5	32.3	196
8	Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. *Nature Medicine*, **2018**, 24, 563-571	50.5	649
7	Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. *Nature*, **2018**, 560, 382-386	50.4	1058
6	Non-conventional Inhibitory CD4Foxp3PD-1 T Cells as a Biomarker of Immune Checkpoint Blockade Activity. *Cancer Cell*, **2018**, 33, 1017-1032.e7	24.3	81
5	Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma. *Pigment Cell and Melanoma Research*, **2018**, 31, 73-81	4.5	22
4	A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. *British Journal of Cancer*, **2018**, 119, 1200-1207	8.7	59
3	T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. *Nature*, **2017**, 545, 60-65	50.4	850
2	Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. *Science* , **2016**, 354, 1160-1165	33.3	618
1	Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. *Cell*, **2016**, 167, 1540-1554.e12	56.2	538